CBN vs CBG vs THCV: minor cannabinoids explained, without the hype

Quick answer: CBN, CBG and THCV are minor cannabinoids, compounds present in small amounts next to THC. CBN forms as THC ages and oxidizes and is weakly intoxicating at most. CBG comes from CBGA, the acid most other cannabinoids are built from, and appears non-intoxicating. THCV can feel intoxicating at higher doses. Human research on all three is thin: a handful of small trials, most since 2016.

Here's what most product pages skip: nobody has settled what any of these compounds reliably does in people. We'd rather show you what's known, what isn't, and how to tell on a label.

What are minor cannabinoids?

Minor cannabinoids are the compounds that usually show up at under 1 percent of a flower's weight, next to the 15 to 30 percent THCA on a typical adult-use flower label. The plant makes more than 100 of them. Few have been studied in humans.

"Minor" describes quantity, not importance or potency. It's a chemistry word that marketing has quietly turned into a promise.

Most start as acids. The plant builds CBGA first, then enzymes convert it into THCA, CBDA or CBCA, hence the "mother cannabinoid" nickname. Heat turns THCA into THC, which is the whole point of decarboxylation. THCV follows a parallel route from a different starting molecule, so it's rare in most modern cultivars.

CBN vs CBG vs THCV: the reference table

"Evidence level" here means human research only. A result in mice tells you what's worth studying, not what happens when you eat a gummy.

What is CBN, and does it get you high?

CBN is what THC turns into as it ages. Oxidation converts THC to CBN, faster in heat, light and open air, so an old jar tests higher in CBN and lower in THC than it did at harvest. On its own, CBN is weakly intoxicating at most.

CBN binds the CB1 receptor, the one mainly behind THC's high, roughly ten times less tightly than THC. A tiny 1975 study by Karniol and colleagues found oral CBN alone looked a lot like placebo. Treat that as a clue, not a verdict.

What does the research say about CBN and sleep?

Very little that's settled. CBN became "the sleepy cannabinoid" in marketing long before anyone tested it properly. A 2021 review in Cannabis and Cannabinoid Research by Jamie Corroon concluded there wasn't enough published human research to support the sleep claims.

Trials since then point in different directions:

• 2023, Experimental and Clinical Psychopharmacology: 321 self-described poor sleepers took 20 mg CBN, CBN plus CBD, or placebo for seven nights. The CBN-only group reported fewer nighttime awakenings. Everything was self-reported at home.

• 2024, Pharmaceuticals: about 1,000 participants compared three doses of a proprietary CBN product against melatonin and placebo, with self-reported outcomes. It tested the manufacturer's own product.

• 2026, Journal of Sleep Research: a University of Sydney team gave 20 adults with diagnosed insomnia one 30 mg or 300 mg dose in a sleep lab. Neither dose met the main goal, less time awake after falling asleep. The 300 mg dose moved some secondary measures, and the authors called for larger trials.

Note that 300 mg is far more than the 5 or 10 mg printed on many CBN gummies. And most shelf products pair CBN with THC or melatonin, so whatever someone feels can't be pinned on CBN. Customers tell us they mostly notice these products when THC is in the mix. That's anecdote, not data.

What is CBG, and why is it called the mother cannabinoid?

CBG is the neutral form of CBGA, the acid the plant converts into THCA, CBDA and CBCA. Since most CBGA gets used up that way, mature flower usually carries only a trace of CBG. It appears to be non-intoxicating.

CBG-heavy plants carry little THC, which is why most concentrated CBG products come from hemp.

What has CBG been tested for in people?

Almost nothing yet. The first controlled human trial, from Carrie Cuttler's team at Washington State University, appeared in Scientific Reports in July 2024. Thirty-four healthy, experienced cannabis users took 20 mg of hemp-derived CBG or placebo at home, observed over Zoom.

On self-rated anxiety and stress scales, scores came in lower after CBG than after placebo, and participants did slightly better on one memory test. That is a single early result, not an established effect. Intoxication ratings stayed under 1 on a 10-point scale in both conditions. The authors flagged the limits: a small, non-clinical sample and one modest dose. One study is a starting line.

What is THCV, and is it intoxicating?

THCV is a chemical cousin of THC with a shorter side chain. Whether it feels intoxicating depends on dose: at low doses, trial participants mostly didn't notice it. At high doses, they did.

The clearest human data comes from a 2023 dose-ranging study in Cannabis and Cannabinoid Research. Healthy adults took single oral doses of delta-8 THCV (a close variant) from 12.5 mg to 200 mg. At 100 and 200 mg, they rated a clear drug effect. The part that rarely makes the product page: 78 of 79 urine drug screens taken eight hours after active doses came back positive for THC. If you're tested at work, that result matters more than any claim on the box.

A 2016 King's College London pilot led by Amir Englund gave 10 healthy men THCV for five days before a THC dose. Ten people can't carry a conclusion.

The "diet weed" nickname you'll see online comes from animal studies and marketing, not established human results.

Why are minor cannabinoids marketed so hard?

Because a new molecule is a new product line. For years these compounds came mostly from the hemp market, where the 2018 Farm Bill's 0.3 percent delta-9 rule left room for almost any other cannabinoid. Hemp brands needed something to sell besides CBD, and every rare compound became a category.

Rarity sells, even when rare just means the plant turned it into something else. A promising rat study gets repeated until it sounds like a human finding. And a claim costs nothing to write, while the trial costs years.

There's a supply wrinkle too: a lot of commercial CBN is made by chemically converting CBD or THC. The federal hemp redefinition signed November 12, 2025 excludes synthesized and chemically converted cannabinoids from hemp, with that part expected to start November 12, 2026 and most of the rest delayed to December 11, 2026. Our hemp vs dispensary THC drink guide tracks those dates.

How do minor cannabinoids show up on a Maine label or COA?

Maine's testing rule sets a minimum cannabinoid panel of delta-9 THC, THCA, CBD and CBDA, plus calculated total THC and total CBD. CBN, CBG and THCV aren't on that required list. But under the Office of Cannabis Policy's chapter 5 rule (18-691 CMR ch. 5), any other cannabinoid referenced in labeling or marketing has to be tested too.

So if a Maine adult-use package says "CBN," a certified lab should have measured it. A gas-station gummy offers no such promise.

On the certificate of analysis, look for:

• Milligrams, not just a name. "With CBN" means nothing. "2.5 mg CBN per serving" means something.

• The ratio to THC. A gummy with 5 mg THC and 2 mg CBN is, chemically, mostly a THC gummy.

• ND or LOQ. "ND" means not detected. "<LOQ" means below the level the lab can reliably measure. Neither is a dose.

• Acid forms on flower. CBGA may be listed separately from CBG. It converts when heated, like THCA.

Total THC in Maine is delta-9 THC plus THCA times 0.877. Our guide to reading a Maine cannabis label walks through that math. Terpenes often sit on the same COA; our myrcene explainer covers the most common one.

How do you shop for minor cannabinoids honestly?

Buy the measured milligrams, not the story.

1. Find the THC first. Most minor-cannabinoid products in adult-use stores also contain THC, the part you'll definitely feel. Dose by that number.

2. Ignore the adjectives. "Sleepy," "focused," "chill blend": none of those words are tested. The milligram counts are.

3. Start low with edibles. A CBN gummy is still an edible, and Maine labels warn effects can take up to 4 hours. Our edible timing guide explains why.

4. Think about drug tests. THCV and some "THC-free" hemp blends can still trigger a positive screen.

5. Keep a plan B. If a stacked product hits harder than expected, here's what to do if you're too high.

If you're considering any cannabinoid for a health reason, talk to a healthcare provider first, especially if you take other medications.

Asking about CBN or CBG at our St John Street counter

We get the "anything with CBN?" question most weeks. Our Cannabis Guides at the Portland shop on St John Street will pull up the COA and tell you plainly when a product is mostly THC with a small minor-cannabinoid add-on.

On our menu, some of these products land under moods like Unwind or Energize. Those are menu shelves, not medical categories. Read the numbers. If you're new to all this, our first-visit guide covers ID, payment and what to ask.

Frequently asked questions

Does CBN get you high?

On its own, CBN is weakly intoxicating at most. It binds the main cannabinoid receptor roughly ten times less strongly than THC, and a small 1975 human study found little effect from CBN alone. Most CBN products in adult-use stores also contain THC, and the THC is usually what you feel.

What does research say about CBN and sleep?

The evidence is early and mixed. A 2021 review found too little human research to support sleep claims. Later trials include a 2023 study of 321 adults using self-reported outcomes, a manufacturer-run 2024 trial, and a 2026 sleep-lab trial of 20 people that missed its main goal. For any sleep concern, talk with a healthcare provider.

Is CBG psychoactive?

CBG appears to be non-intoxicating. In the first controlled human trial, published in Scientific Reports in 2024, 34 experienced cannabis users took 20 mg of CBG or placebo, and intoxication ratings stayed under 1 on a 10-point scale either way. That is one small study at one dose, so it is a starting point.

Can THCV make you fail a drug test?

It can. In a 2023 dose-ranging study of oral delta-8 THCV, 78 of 79 urine screens taken eight hours after active doses came back positive for THC. Some hemp products sold as THC-free carry similar risk. If you are drug tested for work, treat THCV products as if they contain THC.

Why doesn't every Maine label list CBN or CBG?

Maine's testing rule requires labs to report delta-9 THC, THCA, CBD and CBDA, plus total THC and total CBD. CBN and CBG are not on that minimum list. Any other cannabinoid named in labeling or marketing must also be tested, so a Maine adult-use package that says CBN should reflect a lab measurement.

Is THCA the same as THC?

No. THCA is the acid form the plant actually makes, and it is not intoxicating raw. Heat from smoking, vaping or baking converts it into THC through decarboxylation. That is why Maine calculates total THC as delta-9 THC plus THCA times 0.877, accounting for the weight THCA loses as it converts.

CBN, CBG and THCV are real, measurable compounds with interesting early research and a marketing story that has run well ahead of it. Know which is which. Browse what's in stock and check the lab numbers on our online menu, then order ahead for pickup and bring your questions.